English
Stock of the day
Telix Pharmaceuticals
Telix Pharmaceuticals sees a rise in shares following the US approval for reimbursement of its prostate cancer imaging agent.
(AI video summary)
This video was created on 23 September 2025 for IG audiences by ausbiz.
ASX code: TLX
Reimbursement approval sparks optimism
Telix Pharmaceuticals announced that the United States (US) Centers for Medicare and Medicaid Services approved reimbursement for their prostate cancer imaging agent. Last Friday, Citi began coverage on Telix with a high-risk 'buy' rating, forecasting that the company's base business will exceed market expectations
Market reaction
Telix shares rose 5.6%, showing increased investor confidence. Analysts noted that the company's shares were set for a positive turn following previous regulatory setbacks on two drugs, where the Food and Drug Administration (FDA) requested more information, rather than rejections. Analysts have upgraded their outlook from 'hold' to 'buy', anticipating further positive announcements.
Investment outlook
The recent government funding approval boosts the company’s financial outlook. Analysts suggest that if positive updates continue, Telix's stock may rise 60 to 80% in line with analysts' price targets. However, they suggest focusing on the business's prospects over the volatile share price.
Important to know
This information has been prepared by IG, a trading name of IG Australia Pty Ltd. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Ready to open an IG account?
Start your trading journey now
Contact
New clients
1800 601 799
newaccounts.au@ig.com
Existing clients
1800 601 734
helpdesk.au@ig.com
Lines open
24/7 except 6am to 12pm Saturdays (AEST)
Start a Whatsapp chat
Connect with us
Disclaimers
- CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You do not own or have any interest in the underlying asset. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. Please consider the Margin Trading Product Disclosure Statement (PDS), Risk Disclosure Notice and Target Market Determination before entering into any CFD transaction with us.
- The value of shares, ETFs and ETCs bought through an IG share trading account can fall as well as rise, which could mean getting back less than you originally put in. Past performance is no guarantee of future results.
- Please ensure you fully understand the risks and take care to manage your exposure.
- The information on this website is prepared without considering your objectives, financial situation or needs. Consequently, you should consider the information in light of your objectives, financial situation and needs.
- This website is operated by IG Australia Pty Ltd. IG Australia Pty Ltd is located on Level 32, Queen & Collins, 376-390 Collins Street, Melbourne, VIC 3000. ABN 93 096 585 410, Australian Financial Services Licence No. 515106. Derivatives Issuer Licence in New Zealand FSP No. 684191, NZBN 9429047618251.